Viatris to acquire Pacira BioSciences in a $1.65 billion cash deal
+3 new sources since this summary was written
Viatris Inc. announced a definitive agreement to purchase all outstanding shares of Pacira BioSciences for $36.50 in cash per share, valuing the target at $1.65 billion. The transaction adds the non‑opioid pain products EXPAREL and ZILRETTA to Viatris’ portfolio and is expected to close by the end of 2026, subject to regulatory clearance and a majority tender. Viatris’ CEO Scott A. Smith said the acquisition will broaden the company’s innovative medicines business, while Pacira’s board recommends shareholders accept the offer.
Why it matters
The companies state the deal will be immediately accretive to Viatris’ financial guidance, meaning earnings per share should rise once the acquisition closes. Investors in Viatris can expect the purchase to be funded mainly with cash on hand, limiting impact on leverage, while Pacira shareholders will receive cash at the agreed price and see the stock delist from Nasdaq.
Key facts
- 1Viatris will pay $36.50 in cash for each Pacira share. prnewswire.com
- 2The total equity consideration is $1.65 billion. prnewswire.com
- 3Pacira generated approximately $746 million of revenue in the twelve months ended June 30, 2026. prnewswire.com
- 4Pacira reported about $177 million of adjusted EBITDA for the same period. prnewswire.com
- 5The transaction is expected to close by the end of 2026. prnewswire.com
- 6Viatris plans to finance the purchase primarily with excess cash and the remainder with short‑term borrowings. prnewswire.com
Summary written by AlphAI from 20 of 22 sources. Not investment advice. Figures are as stated by the linked sources.